Literature DB >> 18753989

Mortality trends for liver cancer in Mexico from 2000 to 2006.

Nahum Méndez-Sánchez1, Antonio R Villa, Genaro Vázquez-Elizondo, Guadalupe Ponciano-Rodríguez, Misael Uribe.   

Abstract

UNLABELLED: Hepatocellular carcinoma (HCC) is the most common primary liver cancer, with an estimated incidence of half a million new cases per year around the world. Furthermore, HCC is the third greatest cause of cancer-related death in the world, and most of these deaths are registered in developing countries. Recently it has been suggested that Hispanics in the United States have high rates of HCC, but no information regarding this is available in Mexico. The aim of this study was to investigate recent trends (2000-2006) in HCC mortality rates in Mexico.
METHODS: Data on national mortality (death certificates) reported for the years 2000-2006 by the Health Ministry of Mexico were analyzed (www.salud.gob.mx). HCC as a cause of death was analyzed. Mortality rates were calculated for all population ages. Causes of death related to HCC were selected in accordance with the International Classification of Diseases, 10th Revision, Liver Cancer (C22.0, C22.7, C22.9).
RESULTS: We found that age-adjusted mortality rates were remarkably higher in men than in women in the period 2000-2006. In addition, we found an increase in the general mortality rates of HCC from 4.1 per 100,000 in 2000 to 4.7 per 100,000 in 2006.
CONCLUSIONS: The results of this study suggest an increase in the mortality rate for HCC in the period 2000-2006. HCC will become a significant cause of morbidity and mortality in the near future.

Entities:  

Mesh:

Year:  2008        PMID: 18753989

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  6 in total

1.  Migration from Mexico to the United States: A high-speed cancer transition.

Authors:  Paulo S Pinheiro; Karen E Callahan; Mariana C Stern; Esther de Vries
Journal:  Int J Cancer       Date:  2017-10-12       Impact factor: 7.396

Review 2.  Hepatocellular Carcinoma in Mexico.

Authors:  Laura Esthela Cisneros Garza; Ignacio Aiza Haddad
Journal:  Clin Liver Dis (Hoboken)       Date:  2022-03-10

3.  Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma.

Authors:  Robert G Gish; Richard S Finn; Jorge A Marrero
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-04

4.  Hepatitis B and Hepatitis C Infection Biomarkers and TP53 Mutations in Hepatocellular Carcinomas from Colombia.

Authors:  Maria-Cristina Navas; Iris Suarez; Andrea Carreño; Diego Uribe; Wilson Alfredo Rios; Fabian Cortes-Mancera; Ghyslaine Martel; Beatriz Vieco; Diana Lozano; Carlos Jimenez; Doriane Gouas; German Osorio; Sergio Hoyos; Juan Carlos Restrepo; Gonzalo Correa; Sergio Jaramillo; Rocio Lopez; Luis Eduardo Bravo; Maria Patricia Arbelaez; Jean-Yves Scoazec; Behnoush Abedi-Ardekani; Regina M Santella; Isabelle Chemin; Pierre Hainaut
Journal:  Hepat Res Treat       Date:  2011-10-31

5.  Incidence of hepatocellular carcinoma in outpatients with cirrhosis in Brazil: A 10-year retrospective cohort study.

Authors:  Marcelo Campos Appel-da-Silva; Suelen Aparecida da Silva Miozzo; Isabella de Azevedo Dossin; Cristiane Valle Tovo; Fernanda Branco; Angelo Alves de Mattos
Journal:  World J Gastroenterol       Date:  2016-12-14       Impact factor: 5.742

Review 6.  Liver cancer in Hidalgo State, Mexico: analysis of the status, risk factors and regional public health policy requirements: a cross-sectional correlational study.

Authors:  Rosa Isela Barrera-Cortés; Erika Elizabeth Rodriguez-Torres; Enrique Vázquez-Mendoza; Jesús Carlos Ruvalcaba-Ledezma; Luis Enrique Soria-Jasso; Mario Isidoro Ortiz; Eduardo Fernández-Martínez
Journal:  Sao Paulo Med J       Date:  2022 Jul-Aug       Impact factor: 1.838

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.